Rituximab and lenalidomide for the treatment of relapsed or refractory indolent non-Hodgkin lymphoma: real-life experience.
Cassanello G, Drill E, Rivas-Delgado A, Okwali M, Isgor I, Caron PC, Epstein-Peterson Z, Ghione P, Hamlin P, Lue J, Horwitz SM, Intlekofer AM, Johnson W, Kumar A, Moskowitz A, Noy A, Owens C, Palomba LM, Torka P, Galera P, Zelenetz AD, Salles G, Falchi L.
Cassanello G, et al. Among authors: palomba lm.
Haematologica. 2024 Sep 5. doi: 10.3324/haematol.2024.285600. Online ahead of print.
Haematologica. 2024.
PMID: 39234863
Free article.